



HAL
open science

CART - Carcinose angiogénèse et recherche translationnelle

Rapport Hcéres

► **To cite this version:**

Rapport d'évaluation d'une entité de recherche. CART - Carcinose angiogénèse et recherche translationnelle. 2018, Université Paris Diderot - Paris 7, Institut national de la santé et de la recherche médicale - INSERM. hceres-02031655

HAL Id: hceres-02031655

<https://hal-hceres.archives-ouvertes.fr/hceres-02031655v1>

Submitted on 20 Feb 2019

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

REPORT ON THE RESEARCH UNIT:

Carcinomatosis Angiogenesis and Translational Research (CART)

UNDER THE SUPERVISION OF THE FOLLOWING INSTITUTIONS AND RESEARCH BODIES:

Université Paris Diderot

Institut national de la Santé et de la recherche
médicale - Inserm

ÉVALUATION CAMPAIGN 2017-2018
GROUP D



In the name of Hcéres¹:

Michel Cosnard, President

In the name of the expert committee²:

Andreas Bikfalvi, Chairman of the
committee

Under the decree No.2014-1365 dated 14 November 2014,

¹ The president of Hcéres "countersigns the evaluation reports set up by the expert committees and signed by their chairman." (Article 8, paragraph 5);

² The evaluation reports "are signed by the chairman of the expert committee". (Article 11, paragraph 2).

This report is the sole result of the unit's evaluation by the expert committee, the composition of which is specified below. The assessments contained herein are the expression of an independent and collegial reviewing by the committee.

UNIT PRESENTATION

Unit name:	Carcinomatosis Angiogenesis and Translational Research
Unit acronym:	CART
Requested label:	
Application type:	Renewal
Current number:	U 965
Head of the unit (2017-2018):	Mr Marc POCARD
Project leader (2019-2023):	Mr Marc POCARD
Number of teams:	1

COMMITTEE MEMBERS

Chair:	Mr Andreas BIKFALVI, Université de Bordeaux
Experts:	Ms Marie-Christine BOUTRON-RUAULT, Institut Gustave Roussy Villejuif (representative of Inserm CSS)
	Ms Muriel MATHONNET, CHU Université de Limoges (representative of CNU)
	Ms Gertraud OREND, Université de Strasbourg
	Mr Marc REYMOND, University of Tübingen, Germany
HCERES scientific officer:	Ms Urszula HIBNER
Representatives of supervising institutions and bodies:	
	Mr Francois HIRSCH, Inserm
	Ms Béatrice ISABEY, APHP
	Ms Laurence LOMME, Inserm
	Ms Sylvie ROUSSET, Université Paris 7
	Mr Philippe RUSZNIEWSKI, Université Paris 7

INTRODUCTION

HISTORY AND GEOGRAPHICAL LOCATION OF THE UNIT

The CART unit Inserm U965, one of the very few Inserm surgical research units, was created in 2009 in a partnership with the "Institut des Vaisseaux et du Sang" (IVS), with a focus on angiogenesis and translational research. In 2013/14, IVS scientists left the unit, which was then recreated under the direction of Mr. Marc Pocard with a focus on angiogenesis in peritoneal metastasis (PM). During the last mandate, the group of Ms. Nathalie Kubis was also part of the unit with own research focused on angiogenesis in cerebral plasticity.

The CART unit Inserm U965 research lab is located at Hôpital Lariboisière/ Groupe Hospitalier Fernand Vidal, in close vicinity to the gastrointestinal surgical unit headed by Mr. Marc Pocard, creating a real transfer between bench and bedside.

MANAGEMENT TEAM

The director of the unit is Mr Marc Pocard, M.D. PhD, a board-certified digestive surgeon. He is assisted by Mrs Clarisse Eveno, M.D. PhD for clinical research and by Mr Massoud Mirshahi, PhD for laboratory research.

HCERES NOMENCLATURE

SVE5_4 Cancer.

SCIENTIFIC DOMAIN

The monothematic CART unit is focussing on therapy-driven and disease-driven research on peritoneal metastasis (PM). French surgical oncology in PM:

- 1) Surgical research – oncology;
- 2) Peritoneal metastasis – prevention and therapy;
- 3) Technology for health – photodynamic therapy; drug delivery systems;
- 4) Clinical studies.

UNIT WORKFORCE

Unit workforce	Number 30/06/2017	Number 01/01/2019
Permanent staff		
Full professors and similar positions	6	3
Assistant professors and similar positions	6	5
Full time research directors (Directeurs de recherche) and similar positions	0	0
Full time research associates (Chargés de recherche) and similar positions	1	2
Other scientists ("Conservateurs, cadres scientifiques des EPIC, fondations, industries, etc.")	5	2
High school teachers	0	0

Supporting personnel (ITAs, BIATSSs and others, notably of EPICs)	3	3
TOTAL permanent staff	21	15
Non-permanent staff		
Non-permanent professors and associate professors, including emeritus	1	
Non-permanent full-time scientists, including emeritus, post-docs	4	
Non-permanent supporting personnel	0	
PhD Students	9	
TOTAL non-permanent staff	14	
TOTAL unit		
	33	

GLOBAL ASSESSMENT OF THE UNIT

Peritoneal metastasis (PM) is an emergent topic and a major, unmet societal and healthcare challenge with estimated 16,300 deaths/year in France. During the last period, CART unit has been one of the most active groups in PM research internationally. CART has setup and validated several preclinical models and assessed innovative biomedical technologies for prevention and therapy of PM. The team has several strengths: major unmet medical need, high societal impact, ambitious and innovative research, high competitiveness, own validated models, clinical studies supported by PHRC funding, research contracts with industry, valorization through patents, integration in national and international networks, superior scientific output, worldwide reputation, remarkably successful teaching activity and high level of identification and satisfaction of the team members. For the next research contract, a new structure will be set up – “Carcinose Péritoine Technologie Paris” (CAP Paris-Tech) – with the aim of speeding up and scaling up development and assessment of innovative health technologies in PM by integrating academic and industrial research partners. Funding in the frame of larger national and international competitive research programs is absent. Several tenure-track physicians have been trained within the unit; yet there is a need for more permanent research scientist positions in the laboratory.

The evaluation reports of Hceres
are available online : www.hceres.com

Evaluation of clusters of higher education and research institutions
Evaluation of higher education and research institutions
Evaluation of research
Evaluation of doctoral schools
Evaluation of programmes
Evaluation abroad



2 rue Albert Einstein
75013 Paris, France
T. 33 (0)1 55 55 60 10

hceres.com

[@Hceres_](https://twitter.com/Hceres_)

[Hcéres](https://www.youtube.com/Hceres)